Treatment with anti-KIR3DL2 agents
US11970535B2 · kind B2 · utility
0Cited by
24References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2020 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Jul 27, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.